Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04830124 · ClinicalTrials.gov registry record · Phase 2
Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6
A Phase 2 study, sponsored by Mural Oncology.
- Terminated
- Registry status
- Phase 2
- Development phase
- 173
- Enrollment target
NCT04830124: Clinical Trial Phase 2 study, sponsored by Mural Oncology.
NCT04830124 is a Phase 2 study that was terminated before completion, run by Mural Oncology. The registered enrollment target is 173 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (30% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04830124, a Phase 2 study, was terminated before completion, sponsored by Mural Oncology.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 173 participants
- Enrollment target
Study Summary
This study observes the antitumor activity, safety, tolerability, PK, and pharmacodynamics in patients with inoperable and/or metastatic melanoma
Primary Outcome
* ORR is defined as the number of patients exhibiting a complete response (CR) or partial response (PR) divided by the number of patients who received the study drug * Response will be based on RECIST v1.1 criteria
Interventions
- DRUG Pembrolizumab
- DRUG Nemvaleukin Alfa Subcutaneous
- DRUG Nemvaleukin Alfa Intravenous
- DRUG Nemvaleukin Alfa Intravenous Less Frequent Dosing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 173 participants |
| Start Date | 2021-09-27 |
| Est. Completion | 2025-05-08 |
| Phase | Phase 2 |
Why NCT04830124 stopped before completion
NCT04830124 is an interventional study that assigns participants to a tested intervention. The registered 173 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (30% higher).
The record links to 0 conditions, and to 4 interventions - of which Pembrolizumab is the first listed.
NCT04830124 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04830124 about?
NCT04830124 is a clinical study titled "Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6". This study observes the antitumor activity, safety, tolerability, PK, and pharmacodynamics in patients with inoperable and/or metastatic melanoma
What is the current status of trial NCT04830124?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 173 participants. The study started on 2021-09-27. Estimated completion is 2025-05-08.
What interventions are being tested in trial NCT04830124?
The interventions under investigation include: Pembrolizumab (DRUG), Nemvaleukin Alfa Subcutaneous (DRUG), Nemvaleukin Alfa Intravenous (DRUG), Nemvaleukin Alfa Intravenous Less Frequent Dosing (DRUG).
Who is sponsoring clinical trial NCT04830124?
This trial is sponsored by Mural Oncology, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04830124's enrollment target sits among peer trials
173 397th of 2000 higher than 1,604 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05568719 · 173 participants · Phase 3
Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively
- NCT07070115 · 173 participants · NA
Evaluating Clinical Hiatal Hernia Outcomes Using OviTex®
- NCT07150832 · 173 participants · NA
Efficacy of the I-CARE Digital Health Intervention
- NCT01000259 · 174 participants
Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI